Therapeutic method of treating patients suffering from AIDS and AIDS-related syndromes and asymptomatic HIV-seropositive patients.
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorClaudio De Simone
Life of this patent
Estimating the term…
Abstract
A novel therapeutical utilization of L-carnitine, acyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed, for treating immune and metabolic alterations in patients suffering from AIDS and AIDS-related syndromes and in asymptomatic HIV-seropositive patients. The L-carnitine amount to be administered according to this novel use is about 6-8 grams daily, via the oral route or an equivalent amount of an acyl L-carnitine or a pharmacologically acceptable salt thereof, i.e. three-four times as much the dose usually administered for the already known therapeutic uses of L-carnitine.
Claims3
A method for normalizing the triglyceride and TNF-.alpha. levels in patients in need thereof, which patients suffer from AIDS and AIDS-related syndromes and in asymptomatic HIV-seropositive patients, which comprises administering to said patients about 6-8 g L-carnitine/day or an equivalent amount of a straight or unbranched chain C.sub.2-6 alkanoyl L-carnitine or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.